Please Wait
Applying Filters...
menu
    • menu
    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-08-25

    Virtual Booth

    An Enquiry

    Menu

    Durlobactam

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Innoviva’s ZEVTERA, XACDURO Nominated for 2025 Prix Galien
    Innoviva’s ZEVTERA, XACDURO Nominated for 2025 Prix Galien

    13 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250813478127/en/Innoviva-Specialty-Therapeutics-Antimicrobial-Therapies-ZEVTERA-and-XACDURO-Nominated-for-the-2025-Prix-Galien-USA-Best-Pharmaceutical-Product-Award

    BUSINESSWIRE
    13 Aug 2025
    Share Share
    Zai Lab & Pfizer Announce Collaboration on Antibacterial Drug
    Zai Lab & Pfizer Announce Collaboration on Antibacterial Drug

    21 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241121825806/en

    BUSINESSWIRE
    21 Nov 2024
    Share Share
    Zai Lab, Innoviva's SUL-DUR Approved In China For Pneumonia
    Zai Lab, Innoviva's SUL-DUR Approved In China For Pneumonia

    20 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240519020622/en

    BUSINESSWIRE
    20 May 2024
    Share Share
    Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO
    Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO

    23 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230523005961/en

    BUSINESSWIRE
    23 May 2023
    Share Share
    Results from Phase 3 ATTACK Trial Published in The Lancet Infectious Diseases
    Results from Phase 3 ATTACK Trial Published in The Lancet Infectious Diseases

    11 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230511005905/en

    BUSINESSWIRE
    11 May 2023
    Share Share
    FDA panel backs Innoviva's drug for multidrug-resistant bacterial infections
    FDA panel backs Innoviva's drug for multidrug-resistant bacterial infections

    18 Apr 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-backs-innovivas-drug-multidrug-resistant-bacterial-infections-2023-04-17/

    REUTERS
    18 Apr 2023
    Share Share